Beat the ringing.
Start living again.

Oritone is a personalised tinnitus therapy delivered through accredited audiologists. It uses customised sound — generated from your unique hearing and tinnitus profile — to help the brain reduce its response to the tinnitus signal over time. It is not a masking product or a generic sound generator.

Yes. The therapy uses sound delivered at comfortable listening levels — typically softer than comparable uncustomised stimulation. It is non-invasive, drug-free and designed for daily use. Your audiologist will ensure the prescription is appropriate for your profile before treatment begins.

Most sound-based approaches use generic audio designed to distract from tinnitus. Oritone is different. Your therapy is built specifically from your audiological data — your hearing thresholds, tinnitus pitch, loudness, and sound tolerance levels. The goal isn't to cover up tinnitus. It's to help your brain pay less attention to it, durably, over time.

The therapy is delivered through AirPods 3, AirPods 4, AirPods Pro 2, or AirPods Pro 3, paired with a smartphone or tablet. The AirPods use ear-scanning technology to calibrate the sound to your individual ear canal — an important part of what makes the delivery precise. Your audiologist will confirm compatibility at your initial appointment.

Many patients notice meaningful improvements within four months. Clinical data shows that on average, patients move from a severe tinnitus impact score to a very mild range within that period. Results do vary between individuals.

Oritone was developed by Dr Paul Davis, a tinnitus researcher and audiologist with more than 30 years of experience. Dr Davis is also the inventor of the Neuromonics Tinnitus Treatment, which has helped tens of thousands of people worldwide. Oritone represents his next-generation refinement of that work.

Oritone uses your full audiological profile to generate a highly customised broadband sound therapy. The sounds — based on ocean wave recordings, processed through a 42-step algorithm — are calibrated to your specific hearing and tinnitus characteristics. Listening daily encourages your auditory system to become less reactive to the tinnitus signal over time.

Oritone is currently available through accredited audiologists around Australia. You'll need to see a trained Oritone audiologist, who will assess your candidacy, conduct the required tinnitus and hearing tests, and oversee your treatment program.

Oritone is designed for people with moderate to severe tinnitus — particularly those whose symptoms affect sleep, concentration, relaxation, or quality of life. Around 73% of patients in private audiology practice are considered suitable. Your audiologist will assess you before treatment begins. People with certain conditions — such as significant hearing loss, highly fluctuating thresholds, or complex medical factors — may need to be assessed carefully or referred elsewhere.

The therapy is based on layered ocean wave recordings, transformed and calibrated to your hearing profile. Patients commonly describe the sounds as softer, clearer, and immersive — comfortable enough to use for extended daily sessions.

Not at the original daily intensity. After the active treatment phase, most patients transition to a maintenance schedule of around one to two hours per week to preserve the benefits they've gained.

Across a cohort of patients using the latest treatment algorithms, average Tinnitus Functional Index (TFI) scores dropped from the severe range (62) to very mild (29.6) within four months. More than 80% of patients reported a 40% or greater reduction in tinnitus awareness and disturbance by that point. Objective audiometric measures — including sound tolerance and tinnitus loudness — showed consistent, statistically significant improvements. These outcomes have been replicated across independent clinics.

Clinical outcomes have been replicated across multiple independent audiology clinics, with results that matched or exceeded those from the inventor's own clinic. Larger peer-reviewed and randomised controlled trials are planned. Current evidence is based on a longitudinal clinical cohort study.

A full clinical whitepaper is available on request.